API Product   :    Febuxostat
CEP   :    -
WCC   :    ?
Therapeutic Use    :    Anti-Gout Preparations
Originator   :    TAKEDA PHARM USA
TAKEDA PHARM USA
CAS No.    :    144060-53-7
Trade Name.   :    ULORIC
Molecular Weight   :    316.374 g/mol
Molecular Formula   :    C16H16N2O3S
Febuxostat is used to treat gout. Gout is a type of arthritis in which uric acid, a naturally occurring substance in the body, builds up in the joints and causes sudden attacks of redness, swelling, pain, and heat in one or more joints. Febuxostat is in a class of medications called xanthine oxidase inhibitors.
Febuxostat, sold under the brand names Uloric and Febuday among others, is a medication used in the treatment of chronic gout and hyperuricemia. It inhibits xanthine oxidase, thus reducing production of uric acid in the body. Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998. Teijin partnered the drug with TAP Pharmaceuticals in the US and Ipsen in Europe. Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese Pharmaceuticals and Medical Devices Agency.